Bionor Pharma Names New CEO
Mr Lund has most recently headed up clinical development activities of Astra Zeneca in Europe, Asia and Latin America (43 countries). His previous commercial and management experience also includes positions with Rhone-Poulenc Rorer and Nycomed Imaging.
Mr Lund was one of the four new members who joined the board of directors of Bionor Pharma in May, 2010.
Mr Syvertsen was co-founder and has been CEO of Bionor Pharma since 2004 and during this time has worked to obtain new distribution channels for products based on its soy technology platform. He will continue to support the company during the next few months within Nutraceuticals business area.
Mr Lund said: “Over the last couple of months I have gained an insight into the strong and innovative technology and exciting product portfolio of Bionor Pharma. This is a company with a promising future, and I am looking forward to contributing towards its success.”
Wenche Rolfsen, chairwoman of Bionor Pharma, said: “We are very pleased that Henrik Lund has accepted our offer of the CEO position in Bionor Pharma. His strong international background, clinical development experience, pharmaceutical insight and leadership style is perfectly suited to our needs.
Mr Syvertsen said: “This change in management is a natural step for Bionor Pharma, which over the last few months has been transformed from a nutraceutical company to a biopharmaceutical company with its core business within vaccines for viral diseases. With this in mind it has been our objective to bring in leadership with experience in the key fields where we are active, and Henrik precisely fits this bill.”
Will Mr Lund's experience benefit the company?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.